1. Home
  2. ABOS vs MRCC Comparison

ABOS vs MRCC Comparison

Compare ABOS & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABOS
    SELLHOLDBUYas of 10 hours ago
  • MRCC
    SELLHOLDBUYas of 10 hours ago
  • Stock Information
  • Founded
  • ABOS 1996
  • MRCC 2011
  • Country
  • ABOS United States
  • MRCC United States
  • Employees
  • ABOS N/A
  • MRCC N/A
  • Industry
  • ABOS Biotechnology: Pharmaceutical Preparations
  • MRCC Investment Managers
  • Sector
  • ABOS Health Care
  • MRCC Finance
  • Exchange
  • ABOS Nasdaq
  • MRCC Nasdaq
  • Market Cap
  • ABOS 99.1M
  • MRCC 174.8M
  • IPO Year
  • ABOS 2021
  • MRCC 2012
  • Fundamental
  • Price
  • ABOS $1.63
  • MRCC $8.57
  • Analyst Decision
  • ABOS Strong Buy
  • MRCC Strong Buy
  • Analyst Count
  • ABOS 3
  • MRCC 1
  • Target Price
  • ABOS $9.33
  • MRCC $9.00
  • AVG Volume (30 Days)
  • ABOS 416.5K
  • MRCC 60.4K
  • Earning Date
  • ABOS 11-12-2024
  • MRCC 03-10-2025
  • Dividend Yield
  • ABOS N/A
  • MRCC 11.77%
  • EPS Growth
  • ABOS N/A
  • MRCC 298.01
  • EPS
  • ABOS N/A
  • MRCC 0.60
  • Revenue
  • ABOS N/A
  • MRCC $62,007,000.00
  • Revenue This Year
  • ABOS N/A
  • MRCC N/A
  • Revenue Next Year
  • ABOS N/A
  • MRCC N/A
  • P/E Ratio
  • ABOS N/A
  • MRCC $14.28
  • Revenue Growth
  • ABOS N/A
  • MRCC N/A
  • 52 Week Low
  • ABOS $1.53
  • MRCC $6.97
  • 52 Week High
  • ABOS $5.09
  • MRCC $8.80
  • Technical
  • Relative Strength Index (RSI)
  • ABOS 38.36
  • MRCC 58.91
  • Support Level
  • ABOS $1.53
  • MRCC $8.30
  • Resistance Level
  • ABOS $1.75
  • MRCC $8.80
  • Average True Range (ATR)
  • ABOS 0.13
  • MRCC 0.22
  • MACD
  • ABOS 0.01
  • MRCC 0.02
  • Stochastic Oscillator
  • ABOS 23.81
  • MRCC 67.14

Stock Price Comparison Chart: ABOS vs MRCC

ABOS
MRCC
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober20250246810121416182022ABOS VS MRCC

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use